Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/304% below fair value
$29.94−0.54 (-1.76%)
Close on Nov 13, 2026Market cap $1.54BP/E –Yield 0.00%
Immunocore gross margin
Gross margin is gross profit as a percentage of revenue.
Immunocore's gross margin for the twelve months ending Sep 30, 2026 was 98.9%. For fiscal 2025 it was 98.7%, against 99.1% the year before. The highest annual figure on record is 100.0% in fiscal 2021.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 98.7% | −0.4 |
| FY2024 | Dec 31, 2024 | 99.1% | −0.5 |
| FY2023 | Dec 31, 2023 | 99.6% | +0.2 |
| FY2022 | Dec 31, 2022 | 99.4% | −0.6 |
| FY2021 | Dec 31, 2021 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 99.3% | −0.2 |
| Q2 FY2026 | Jun 30, 2026 | 99.1% | +0.1 |
| Q1 FY2026 | Mar 31, 2026 | 99.6% | +0.5 |
| Q4 FY2025 | Dec 31, 2025 | 97.4% | −2.2 |
| Q3 FY2025 | Sep 30, 2025 | 99.5% | +0.1 |
| Q2 FY2025 | Jun 30, 2025 | 98.9% | +1.2 |
| Q1 FY2025 | Mar 31, 2025 | 99.1% | −0.5 |
| Q4 FY2024 | Dec 31, 2024 | 99.6% | −0.1 |
| Q3 FY2024 | Sep 30, 2024 | 99.4% | −0.1 |
| Q2 FY2024 | Jun 30, 2024 | 97.7% | −1.7 |
| Q1 FY2024 | Mar 31, 2024 | 99.7% | +0.0 |
| Q4 FY2023 | Dec 31, 2023 | 99.7% | – |
| Q3 FY2023 | Sep 30, 2023 | 99.6% | – |
| Q2 FY2023 | Jun 30, 2023 | 99.4% | – |
| Q1 FY2023 | Mar 31, 2023 | 99.6% | – |
See a number that looks wrong?